Nektar Therapeutics (NKTR) Net Cash Flow (2010 - 2026)

Nektar Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $134.5 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 2610.02% year-over-year to $134.5 million in Q1 2026; TTM through Mar 2026 was $110.7 million, a 1235.03% increase from a year earlier, with the FY2025 full-year figure at -$29.1 million, down 424.56% from the prior year.
• Net Cash Flow climbed to $134.5 million in Q1 2026 per NKTR's latest filing, from -$25.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $134.5 million in Q1 2026 and bottomed at -$29.7 million in Q4 2023.
• The 5-year median for Net Cash Flow is $2.2 million (2024), against an average of $7.3 million.
• Across the five-year window, Net Cash Flow sank 373.69% in 2023 and jumped 2610.02% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$17.6 million in 2022, then tumbled by 68.61% to -$29.7 million in 2023, then jumped by 147.59% to $14.1 million in 2024, then tumbled by 283.67% to -$25.9 million in 2025, then surged by 618.84% to $134.5 million in 2026.
• Per Business Quant, the three latest NKTR Net Cash Flow figures stand at $134.5 million (Q1 2026), -$25.9 million (Q4 2025), and -$2.0 million (Q3 2025).